Coreshell and Elixir are the two customers where Anchor's publications face the highest risk of converting milestone into market conclusion. Both companies are in stretches where the decisive evidence generates no public signal.
Coreshell's public narrative shifted from commercial-format cells and planned A-sample delivery (December 2024) through strategic funding (March 2025) to domestic supply-chain sovereignty storytelling by 2026. "China Controls the Battery Supply Chain. Here's How America Breaks Free" is a real story. It also doesn't require Coreshell to have confirmed automaker acceptance of its samples. No reviewed source names an automaker that accepted A-samples (pre-production cells sent for qualification testing) or disclosed qualification results.
Elixir's version is structural rather than rhetorical: favorable company-presented trial data and CE Mark availability outside the U.S., while its own homepage still marks DynamX as investigational in the U.S. CE Mark does not predict FDA PMA (premarket approval) timing.
Both companies fill the vacuum left by invisible milestones with adjacent narratives. Sovereignty. European follow-up data. These narratives are legitimate, but they aren't the evidence that determines commercial outcome. A publication that tracks narrative momentum without policing the gap between milestone and market becomes marketing with better sourcing. The Hysteresis should be mapping what's absent from Coreshell's public record. Clear Path should be measuring the distance between clinical evidence and U.S. market access. Both publications should be making the dark stretch visible to the reader, not routing around it.
Coreshell — what's public: 60 Ah commercial-format cells (Dec 2024). $24M strategic funding anchored by Ferroglobe (March 2025). Manufacturing EVP hire from Ultium Cells (May 2025). Domestic-supply-chain documentary and blog posts (2026).
Coreshell — what's not: Named automaker accepting A-samples. Qualification outcomes. Manufacturing yield. Shipment volume. Any public signal that the sovereignty narrative rests on confirmed commercial traction.
Elixir — what's public: BIOADAPTOR RCT 12-month TLF (target lesion failure, the primary measure of whether a stent works): 1.8% vs. 2.8% for conventional stent. 4-year cardiac death: 0.5% vs. 3.7%. CE Mark availability outside U.S.
Elixir — what's not: FDA PMA submission status. U.S. physician adoption signals. Payer or hospital purchasing behavior. Independent clinical consensus beyond company-presented data.
Dark-stretch test: If the next issue of either publication would read identically whether or not the invisible milestone had occurred, the publication is tracking the company's narrative rather than its evidence base.